According to the terms of the agreement, Innovare will use DelSiTech's technology on its peptide membrane fusion inhibitor
, targeting the envelope protein of human immunodeficiency virus-1.
This agreement allows Innovare to use DelSiTech's technology on its peptide membrane fusion inhibitor
, targeting the envelope protein of human immunodeficiency virus-1 (HIV-1).
The new drug, developed by Frontier Biotechnologies, is the first long-acting fusion inhibitor
tor HIV, and is reported to have fewer side effects on the liver then previous treatments.
Nonetheless, it is clear that when fusion inhibitor
([u.sub.1]) is used without other controls, the number of [CD4.sup.+] T-cells reduces significantly and a longer time is taken before the number increases.
Only one fusion inhibitor
medication is available: enfuvirtide (Fuzeon[R]), also known as T-20 (AIDSinfo, 2016a; FDA, 2016).
Phase II results of GS-5806, an investigational oral RSV fusion inhibitor
in respiratory syncytial virus (RSV), achieved its primary and secondary endpoints of lower viral load and improvement in symptoms.
Any molecule which can block the process of six-helix bundle formation by targeting the Gp41 NHR would be a good lead as a HIV fusion inhibitor
Data regarding treatment duration and choice of ARVs were matched with the national database and interpreted according to ARV classes: PI, NNRTI, NRTI (nucleoside reverse-transcriptase inhibitors), integrase inhibitor, CCR5-receptor antagonist, fusion inhibitor
Their topics include a critical academic perspective on marketing antimicrobial peptides, conotoxin-based leads in drug design, kyotorphin derivatives as an example of turning endogenous peptides into new analgesics, sifuvirtide as a novel HIV-1 fusion inhibitor
, translational research on amylin agonism, and developing antibody fragments for therapeutic applications.
FDA-Approved Antiretroviral Agents Nucleoside RTIs Nonnucleoside RTIs Protease inhibitors abacavir (ABC) delavirdine (DLV) atazanavir (ATV) didanosine (ddl) efavirenz (EFZ) darunavir (DRV) emtricitabine (FTC) etravirine (ETV) fosamprenavir (Fos-APV) lamivudine (3TC) nevirapine (NVP) indinavir (IDV) stavudine (d4T) lopinavir/r (LPV/r) zidovudine (ZDV) nelfinavir (NFV) ritonavir (RTV) saquinavir (SQV) tipranavir (TPV) Nucleotide RTI Integrase inhibitor Fusion inhibitor
tenofovir DF (TDF) raltegravir (RAL) enfuvirtide (T-20) CCR5 antagonist maraviroc (MVC) Notes: Six fixed-dose combinations are approved by the Food and Drug Administration.
To potently inhibit HIV-1 entry, a C-HR targeting fusion inhibitor
can have a relatively low affinity, but an N-HR targeting fusion inhibitor
must bind extremely tightly.
IPF has demonstrated to have both fusion inhibitor
and immunomodulator capabilities during in vitro studies with no viral resistance.